



**Poster Session 5**  
**12:30 – 2:00 p.m.**  
**Friday, December 13**

P5-01-01: Longitudinal monitoring of quality of life in patients with de novo metastatic inflammatory breast cancer (mIBC) - a protocol in progress	Faina Nakhlis
P5-01-02: Is breast-conserving surgery after neoadjuvant therapy safe for locally advanced breast cancer?	Yedda Reis
P5-01-03: Boost delivery to the tumor bed in breast cancer patients who have achieved pCR confirmed by VAB without surgery	Alexander Emelyanov
P5-01-04: Determination and clinical characteristics of bone pseudoprogression on advanced first-line therapy in metastatic breast cancer	Yuan Yuan
P5-01-05: Clinicopathological features and outcomes of ER-low/HER2-low expression in de novo metastatic breast cancer: a preliminary cohort study	Chongxi Ren
P5-01-06: Discerning the consequences of type I interferon signaling in RON expressing breast cancer	Levi Fox
P5-01-07: Use of Neoadjuvant Chemotherapy for Local and Regionally Recurrent Triple Negative and HER2+ Breast Cancer	Mary Mrdutt
P5-01-08: Perceptions and behaviors of US oncologists treating HR-positive HER2-negative metastatic breast cancer in second-line	Leah Park
P5-01-09: Improving ESR1 Mutations Detection in Breast Cancer Circulating Tumor DNA: Comparative Analysis of Enrichment Techniques	Anna Gasior
P5-01-10: Clinical and pathologic factors associated with progression-free survival in patients with metastatic hormonal breast cancer treated with ICDK4/6	Juan Manuel Tovar Cabrera

P5-01-11: HER2-low is associated with longer progression-free survival in HR+/HER2- advanced breast cancer after cyclin-dependent kinase inhibitor 4/6 failure.	José Antonio García Gordillo
P5-01-12: Subsequent Treatments After Progression On Cyclin-Dependent Kinase 4/6 Inhibitors - A Multicentric Portuguese Real-world Data Study	Ana Rita Rego Freitas
P5-01-13: Efficacy of abemaciclib and endocrine therapy on the overall survival for advanced ER-positive/HER2-negative breast cancer according to the treatment of lines	Eriko Tokunaga
P5-01-14: Real world evidence of continued CDK4/CDK6 inhibition and endocrine therapy beyond progression on a prior CDK4/6i in women with hormone receptor positive (HR+), Her2 negative advanced breast cancer (MBC).	Roberto Sánchez-Reyes
P5-01-15: Clinical verification of HR-positive/HER2-0 and HER2-low metastatic breast cancer patients treated with CDK4/6 inhibitors	Wataru Goto
P5-01-16: m6A reader YTHDF3 promotes epithelial-mesenchymal transition and metastasis through facilitating Notch2 translation in breast cancer	Hong-Yu Chen
P5-01-17: Unveiling epithelial cell heterogeneity in lobular breast carcinomas through single cell RNA sequencing	Silvia González-Martínez
P5-01-18: ESR $\alpha$ and RASSF1A promoter methylation changed significantly in benign tumors and in the early event of breast cancer progression	Yasmine Kanaan
P5-01-20: Elucidating novel pro-apoptotic consequences of an altered sphingolipidome in endocrine therapy-resistance.	Purab Pal
P5-01-21: Epigenetic changes induced by combinatorial pterostilbene and resveratrol in Her2-positive and triple-negative mammary cancer via gut microbiome-metabolome axis modulation.	Sebanti Ganguly
P5-01-22: Establishing an Ex-Vivo Model for Postpartum Involution and Breast Cancer Susceptibility	Samaneh Karami
P5-01-23: Linking Spatial Distribution of Core Fucosylated N-Glycans to Triple Negative Breast Cancer Outcomes	Danielle Scott
P5-01-24: PPFIA4 mediates glucose metabolism reprogramming to alter the biological characteristics of breast cancer	Haochen Yu
P5-01-25: Romidepsin Targets HDAC1/2 to Induce Ferroptosis in TNBC Enhancing Chemosensitivity to Eribulin	Weipeng ZHAO

P5-01-26: Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer	Nina Ilic-Widlund
P5-01-27: The relation between local tumor infiltrated T cells (TILs) and neutrophil-to-lymphocyte ratio (NLR) of peripheral blood in patients with De novo Stage IV breast cancer	Rie Sugihara
P5-01-28: A comprehensive analysis of NTRK3 expression in breast cancer	Jae-Ho Lee
P5-01-29: Development of a Novel Antigen Presentation Assay in Triple-negative Breast Cancer	Mei Li
P5-01-30: Prolactin-Enhanced Iron Uptake via CD44 and Its Impact on Breast Cancer Metastasis	Reagan Farrell
P5-02-01: Does Community-Level Distress Correlate with the Risk of Developing Lymphedema Among Breast Cancer Patients?	Fardeen Bhimani
P5-02-02: Gender Disparities in the National Institutes of Health Funding for Gastrointestinal Oncology.	Janta Ukrani
P5-02-03: Racial Disparity in the Genomic Landscape of Patients with Breast Cancer and Association with Clinical Outcomes	Arya Mariam Roy
P5-02-04: Factors Predicting Transition to Independent Grants among NIH K awardees in Breast Oncology	Jayasree Krishnan
P5-02-05: OncotypeDx Molecular Assay Association with Breast Cancer Outcomes in Different Racial Groups	Reine Abou Zeidane
P5-02-07: Racial Disparities in Breast Cancer Outcomes Based on MammaPrint Scores	Reine Abou Zeidane
P5-02-08: Assessing Medical Mistrust among Black Adults with and without a Family History of Breast Cancer	Mya Roberson
P5-02-09: Evaluating the Clinical Utility of Bioimpedance Spectroscopy for Early Detect of Breast Cancer-Related Lymphedema in Ethnic Minority Populations	Fardeen Bhimani
P5-02-10: Factors and Trends in Place of Death Among Breast Cancer Patients: A Population-Based Study in Brazil	Jesse Lopes da Silva
P5-02-11: Health-care disparities between ethnically and religiously diverse population with advanced breast cancer	Shani Paluch-Shimon
P5-02-12: Increasing clinical trial enrollment rates of black women with breast cancer through Patient Navigation and Community Education programs	Tina Chai
P5-02-14: The Value of RNASeq in Addressing Breast Cancer Disparities Among Minority Populations: A Focus on African American Women	Catalina Esguerra

P5-02-15: Impact of socioeconomic factors on stage of diagnosis and mortality among breast cancer patients	Ana Sandoval-Leon
P5-02-16: Thymidine kinase activity as a prognostic biomarker for first line CDK4/6 inhibitor efficacy in the Personalised Disease Monitoring in Metastatic Breast Cancer study	Sacha Howell
P5-02-17: Concordance Analysis of Non-Invasive determination techniques of PIK3CA and ESR1 mutations in patients with advanced luminal breast cancer. Study CANIPE	Teresa Curiel
P5-02-18: mRNA Expression of ER, PR, Her2 and Ki67 compared to immunohistochemistry in 374 breast cancer core needle biopsies to validate and benchmark routine diagnosis using the APIS Breast Cancer Subtyping Kit	Anne-Sophie Wegscheider
P5-02-19: Why Are We Failing to Cure So Many Cases of Lobular Breast Cancer?	Robert Smith
P5-02-20: Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer	Jacqueline Tao
P5-02-21: Tumorspheres derived from circulating cancer stem cells in breast cancer patients exhibit elevated levels of immune regulatory molecules	Monika Pizon
P5-02-22: Urinalysis of breast cancer patients identifies disease-specific miRNA patterns.	Elmar Stickeler
P5-02-23: Unveiling the Antitumor Mechanism of abemaciclib in Human Breast Cancer Through Circulating Tumor Chromatin Analysis	Mamoru Takada
P5-02-24: Targeting FOXK2 signaling in breast cancers with FOXK2 amplification/overexpression and PIK3CA oncogenic mutations: a promising therapeutic strategy?	Hong Zhang
P5-02-25: Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women	Marta Tapia
P5-02-26: Trial in progress: Imatinib to convert triple negative breast cancer into estrogen receptor (ER) positive breast cancer - a window of opportunity trial	Sophie Lehn
P5-02-27: Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients	Neha Nagpal
P5-02-28: Genomic markers of sacituzumab govitecan (SG) response in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer	Alexis LeVee
P5-02-29: Redefining PARP inhibitor paradigms to target DNA repair dysfunction in lobular breast cancer	Matthew Sikora

P5-03-01: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation	Matthew Goetz
P5-03-03: Pertuzumab and Trastuzumab Biosimilars in Real-Life Association for the First-Line Treatment of HER2-Positive Metastatic Breast Cancer: the prospective, observational PETRA study	Gilles Freyer
P5-03-04: The effectiveness of post-T-DXd treatments in patients with HER2-positive metastatic breast cancer: A nationwide Japanese cohort study (EN-SEMBLE)	Kazuki Nozawa
P5-03-05: AI Based Quantitative Estimation of HER2 Protein Expression in Low and Ultra Low Ranges	Anya Tsalenko
P5-03-06: Correlation of Mutational Changes in Circulating Tumor DNA with Clinical Outcomes in HER2 Positive Metastatic Breast Cancer	Surbhi Warrior
P5-03-07: <sup>64</sup> Cu-DOTA Trastuzumab -PET to predict CNS response to Trastuzumab-deruxtecan (TDXd) in patients with metastatic HER2 low and HER2 positive breast cancer	Joanne Mortimer
P5-03-08: Characteristics of ESR1-Mutant HER2 Positive Metastatic Breast Cancer (MBC)	Janice Lu
P5-03-09: Evaluating Post-T-DXd Treatment Strategies in HER2-positive Metastatic Breast Cancer	Sophia Zelizer
P5-03-10: Safety and Preliminary Efficacy of Tucatinib and Alpelisib in Patients with HER2-positive PIK3CA-Mutated Metastatic Breast Cancer	Elena Shagisultanova
P5-03-11: DEMETHER: A single-arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer	Javier Cortés
P5-03-12: Liquid Cytopathology for HER2 Status in Breast Cancer: Beyond Tissue Biopsy	Elisabetta Molteni
P5-03-13: Trastuzumab emtansine versus disitamab vedotin for HER2-positive metastatic breast cancer: a multicenter retrospective real-world study	Huihui Li
P5-03-14: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting	Yuxin Mu

P5-03-15: EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan	Sara M. Tolaney
P5-03-23: Unveiling Guillain-Barre Syndrome as a Paraneoplastic Sequelae of Breast Cancer	Rachelle Diane Maravilla
P5-03-25: Trastuzumab deruxtecan (T-DXd) in leptomeningeal metastases from HER2-altered cancers	Qian Ma
P5-03-26: Concurrent use of trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: a single-center experience and review of the literature	Jihane Bouziane
P5-03-27: Updated Real-World Evidence on the Efficacy and Safety of Inetetamab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Previously Treated with Trastuzumab	Yangyang Duan
P5-03-28: Case report: interstitial lung disease in a patient with metastatic breast cancer treated with radiotherapy and trastuzumab deruxtecan	Thamilyn Saruwatari
P5-03-29: Impact of the PIK3CA mutation on clinical outcomes of patients with HER2+ metastatic breast cancer; a real-world study	Pegah Farrokhi
P5-03-30: Real-world data on the use of trastuzumab deruxtecan in breast cancer patients at a tertiary hospital in Ourense, Spain.	Leticia Iglesias Rey
P5-04-02: The Breaking Point: Understanding Healthcare Costs, Financial Strain, and Coping Mechanisms Used by Metastatic Breast Cancer Patients with Medicare Coverage	Fran Castellow
P5-04-03: The impact of neighborhood-level social determinants on breast cancer mortality after a second primary breast cancer.	Ifeoma Nwigwe
P5-04-04: Comprehensive Analysis of Breast Cancer Treatment Delays in Brazil: A Six-Year Study	Marcelo Antonini
P5-04-05: Impact of racial and socioeconomic disparities on overall survival in Invasive Lobular Carcinoma	Toru Yoshino
P5-04-06: Demographic differences in an SHG-based prognostic indicator.	Edward Brown
P5-04-07: Assessing COVID-19 vaccination status and symptoms in persons with a history of breast cancer	Anamaria Lopez
P5-04-08: The role of sexual orientation in mammogram screening adherence among deaf, deaf blind, and hard of hearing women.	Erika Bergeron

P5-04-09: A nationwide database study breast cancer in younger women: Chile 1997-2023	Claudio Salas
P5-04-10: Age at Breast Cancer Diagnosis and Associated Demographic Factors: An Epidemiological Study in Brazil	Jesse Lopes da Silva
P5-04-11: Quality of life and psychosocial disparities between ethnically and religiously diverse population with advanced breast cancer	Michal Braun
P5-04-12: Comparative Analysis of Female Breast Cancer: Incidence, Mortality, and 5-Year Survival Rates Across Races and Diagnosis Stages in Different Age Groups	Navneet Kaur
P5-04-14: Variants of PEA3, SLC2A4RG, PALB2, and XIRP2 and their relationship with Genetic Ancestry across Breast Cancer Patients from different Racial/Ethnic groups.	Grace Vélez Crespo
P5-04-15: Examining the association between biological age, stress, and resilience among diverse breast cancer survivors using the NIH All of Us Dataset	Bathsheba Aklilu
P5-04-16: Stromal tumor-infiltrating lymphocytes-based model predicts efficacy for neoadjuvant therapy in HER2-low early breast cancer	Zhuxi Duan
P5-04-17: Association Between Ki-67, Body Mass Index, and Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients	Tanmayi Pai
P5-04-18: Clinical Validation of an Ultra-Sensitive ctDNA NGS Assay in HR-Positive, HER2-Negative Breast Cancer Patients	Haoran Tang
P5-04-19: Gene variants in circulating tumor cells as markers of resistance in patients with metastatic breast cancer receiving CDK4/6 inhibitors	Sabine Kasimir-Bauer
P5-04-20: Predictive and Prognostic Value of Magee Equation 3 and Tumor-Infiltrating Lymphocytes in HR+ HER2-Negative Breast Cancer: A Retrospective Cohort Study in a tertiary hospital in Sao Paulo, Brazil.	Rodrigo Goncalves
P5-04-21: Decoding breast cancer: unveiling the role of hallmark genes in tumor progression and prognosis	Balazs Gyorffy
P5-04-22: Prognostic value of circulating tumor DNA (ctDNA) in early triple-negative breast cancer (TNBC): A systematic review and meta-analysis	Diana Zhang
P5-04-23: Genomic Investigation of Angioma in Mammary Cancer	Rachel Geiser
P5-04-24: ATV-1601 is a Potent and Selective Allosteric Inhibitor of AKT1E17K and Shows Profound and Durable Regressions in AKT1E17K-Driven Patient Derived Xenograft Models	Shomit Sengupta

P5-04-25: Detection of Human Epidermal Growth Factor Receptor 2 (HER2) in Cultured Circulating Tumor Cells (CTCs) Isolated from Peripheral Blood of Breast Cancer Patients	Ying Chang
P5-04-26: Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study	Han Fang Cheng
P5-04-27: A Novel Patient-Derived Xenograft Model of Inflammatory Breast Cancer	Tiffany Cheung
P5-04-28: Subtype by PAM50 changes after Neoadjuvant Endocrine therapy, from A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in ER+HER2- Operable Breast Cancer	Rie Nakagawa
P5-04-29: Investigating the expansion of 95-gene signature (Curebest® 95GC Breast) indication for predicting the risk of recurrence in patients with ER-positive and lymph node-positive breast cancer.	Asako Tsuruga
P5-04-30: Holographic and molecular characterization of early disseminated cells from breast cancer patients	Kaylee Kamalanathan
P5-05-01: Real World Treatment Patterns and Outcomes in Her-2 Positive Metastatic Breast Cancer Patients with Brain Metastases	Mariella Mestres-Villanueva
P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial	Biyun Wang
P5-05-03: Neratinib-based combination treatments for patients with HER2-positive breast cancer brain metastases	Sarah L. Sammons
P5-05-04: Final results of a phase II trial evaluating paxalisib with trastuzumab for patients (pts) with HER2 positive metastatic breast cancer with active brain metastases.	Jose Leone
P5-05-05: Incidence and Risk Factors of Brain Metastasis in HER-2 Positive Primary Breast Cancer: A Retrospective Analysis	Anu Gaba
P5-05-06: Factors Influencing Long-Term Remission in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-based Therapy: A Single-Center Retrospective Analysis	Aydah AlAwadhi



P5-05-07: A prospective, multicenter, single-arm clinical study of inetetamab combined with pyrotinib and capecitabine/vinorelbine in the treatment of HER2-positive metastatic breast cancer resistant to previous trastuzumab treatment	Yan Xue
P5-05-08: Inetetamab-base regimens for patients with HER2-positive metastatic breast cancer and brain metastases: a real-world retrospective study	Liping Chen
P5-05-09: Trastuzumab deruxtecan combined with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: an exploratory, multi-center, single-arm, phase Ib/II study (TROPHY)	Ying Fan
P5-05-10: Real-world treatment patterns and clinical outcomes of first-line therapy and first-line maintenance therapy in patients with human epidermal growth factor 2-positive metastatic breast cancer	Agreen Hadadi
P5-05-11: Systematic review of ADCs vs chemotherapy in 2L+ Her2+ mBC	Mark Gramling
P5-05-12: Real-world outcome of patients with HER2-positive metastatic breast cancer who were treated with inetetamab-containing regimens: A multicenter retrospective analysis conducted in China	Huihui Li
P5-05-13: Assessment of efficacy and pulmonary toxicity of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in United Arab Emirates	Mohammad Hourani
P5-05-14: Real-World Treatment Patterns and Clinical Outcomes of Inetetamab combined with pyrotinib plus chemotherapy in Her-2 negative metastatic breast cancer patients : a multi-center retrospective study	Huanhuan Zhou
P5-05-15: Intrinsic subtype expression between durable and poor responder during anti-HER2 treatment in triple-positive breast cancer	Jieun Lee
P5-05-16: Real-world analysis of inetetamab-based therapy for the treatment of HER2-positive advanced breast cancer.	Cailing Lin
P5-05-17: Trastuzumab deruxtecan for HER2-positive and HER2-low breast cancer brain metastasis: Results from a single-institution retrospective study.	Chunfang Hao
P5-05-18: Characterizing Patient Experience and Decision Making Associated with Considering Stopping or Pausing HER2-targeted Treatment for MBC Population Using a Questionnaire	Martha Carlson

P5-05-19: Complete response with Alpelisib and Trastuzumab in a patient with ER/PR-negative, HER2-positive refractory metastatic breast cancer	Farah Shah
P5-05-20: Efficacy of Fam-Trastuzumab Deruxtecan-nxki (T-DXd) in Hormone Receptor-Negative, HER2-3+ Metastatic Breast Cancer: A Case Study	ALIYA KHAN
P5-05-21: Tumor/stromal infiltration of Natural Killer (NK) cells and overall survival (OS) in patients (pts) with metastatic (met) HER2+ breast cancer (BC).	Denis M Collins
P5-05-22: ARX788 for patients with HER2-positive advanced breast cancer: characterization, time course, and monitoring and management of adverse event from the phase III ACE-Breast-02 study	Jian Zhang
P5-05-23: Metastatic HER2+ breast cancer across a decade – who does not receive treatment?	Kathrine F. Vandraas
P5-05-24: RC48-ADC (Disitamab vedotin, a HER2-directed antibody-drug conjugate) in Combination with Pyrotinib for Trastuzumab-treated HER2-Positive Recurrent or Metastatic Breast Cancer: A Phase Ib/II Study	Xinrui Liang
P5-05-25: Real-world Treatment for HER2-positive (HER2+) Metastatic Breast Cancer Patients and Compliance to Guideline Recommendations: HER2 REAL Brazil Cohort	Carlos Barrios
P5-05-27: Multi-Institutional Quality Improvement on HER2-Positive and HER2-Low Metastatic Breast Cancer	Reshma Mahtani
P5-05-28: Fully human internalizing anti-HER2 antibody with distinct epitope inhibits tumor formation of trastuzumab resistant breast cancer cells,	Ginette Serrero
P5-05-29: Real-world efficacy and safety of inetetamab-based therapy in patients with HER2- positive metastatic breast cancer with prior trastuzumab exposure: A prospective real-world study.	Dedian Chen
P5-05-30: Unlocking the Therapeutic Potential of T-DXd (Enhertu): Mechanisms of Action in HER2-Low Cancers and Immunomodulatory Effects	Zachary Hartman
P5-06-01: Patient poverty burden influences the molecular biology of ER+ breast cancer	Jerry DeWitt
P5-06-02: Comparison of lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment via comprehensive genomic profiling and whole-genome sequencing of circulating tumor DNA	Marija Balic

P5-06-03: Single-cell and spatial approach to study endocrine therapy sensitivity in breast cancer models with heterogeneous estrogen receptor expression	Svetlana Semina
P5-06-04: Luminal subtype independent immune-enrichment in inflammatory breast cancer based on commercially available tumor portrait.	Azadeh Nasrazadani
P5-06-05: Targeting Triple-Negative Breast Cancer with a Novel Adeno-Associated Virus-mediated Therapy	Fokhrul Hossain
P5-06-06: The Mechanistic Role of BRCA1 DNA and RAD51 Binding in DNA Double-Strand Break Repair	Angela Jasper
P5-06-07: Luminal-to-basal subtype conversion is governed by TP53-GATA3 mutational status and is targetable by MAPK inhibition in patients with breast cancer	Min Hwan Kim
P5-06-08: Molecular features of Pregnancy Associated Breast Cancer from a tertiary care cancer centre in India.	Dr. Jyoti Bajpai
P5-06-09: Evaluating Functional Impacts of GATA3 Mutations in Breast Cancer Using Mesenchymal-to-Epithelial Transition Model	Aerica Nagornyuk
P5-06-10: Clinical and Transcriptomic Study of Matched Primary Breast Cancer and Brain Metastasis	Ajay Dhakal
P5-06-11: Serine Starvation Inhibits SRSF Protein Expression and Modulates RNA Splicing in Breast Cancer Cells	Philippa Burns
P5-06-12: BreastSubtypeR: Streamlining Intrinsic Molecular Subtyping in Breast Cancer Research with a User-Friendly R Package	qiao yang
P5-06-13: ARRB1 cooperates with estrogen receptor to drive endocrine resistance in ER-positive breast cancer	Qian Xu
P5-06-14: PTBP1 is associated with tumor proliferation as an oncogene that regulates breast cancer metabolism.	Manabu Futamura
P5-06-15: Nucleosome binding affinity of the pioneer factor GATA3 influences chromatin reprogramming in breast cancer	Jill Goodman
P5-06-16: Preclinical Characterization of LAE118, a Novel Allosteric Pan-mutant Selective PI3Ka Inhibitor	Ming Li
P5-06-17: The addition of ribociclib, palbociclib or abemaciclib to the next generation oral SERD, camizestrant, delivers greater anti-tumour efficacy in a range of ESR1wt and ESR1m breast PDX models	Claire Crafter
P5-06-18: The Role of PARP1-mediated FOXA1 ADP-ribosylation in Breast Cancer Biology	Cristel V. Camacho
P5-06-19: Single-cell transcriptional features of human breast tumors and model systems	Julia Altman

P5-06-20: Advances in Molecular Characterization and Targeted Therapeutics for Lobular Breast Cancer: Enhancing Personalized Treatment Strategies	Mohammed Imad Malki
P5-06-21: Longitudinal profiling of cell-cell interactions in estrogen receptor positive breast cancer patients treated with aromatase inhibitors: insights from single cell RNA sequencing analysis	Alida van Meeteren
P5-06-22: Harnessing the Power of the Variant: Breast Cancer's Strategic Incorporation of the Histone H2A.J	Rana Gbyli
P5-06-23: NDRG1-AKT signaling promotes tumor stemness in inflammatory breast cancer	Emilly Schlee Villodre
P5-06-25: Dose-dependent Effects of Estrogen on Genomic Regulation in Breast Cancer Cells	Hyung Bum Kim
P5-06-26: APOBEC3B And DNA Damage Repair As Synthetic Lethal Pairs	Bojana Stefanovska
P5-06-27: OXTR inhibits breast cancer cell invasion and metastasis by regulating the post-translational modification of the COL1A1 protein to accelerate its degradation through the lysosomal pathway.	Qing Shao
P5-06-28: Characterization of cell type specific distal cis-regulatory elements from 5' scRNA-seq in estrogen receptor positive breast cancer patients treated with aromatase inhibitors	Villads Winton, Xavier Tekpli
P5-06-29: Tumor and endothelial cell-specific methylation alterations identified in breast cancer with epigenetic deconvolution	Barbara Karakyriakou
P5-06-30: Distinct ERBB2 amplification patterns in HER2-positive breast cancers with BRCA1/2 mutations and their therapeutic implications	Kyung-Hun Lee
P5-07-01: A Systematic Review and Meta-Analysis on Surgical Outcomes of Ligasure™ versus Conventional Methods in Axillary Lymph Node Dissection for Breast Cancer Patients	Maria Gloria Elisha Casas-Siena
P5-07-02: Effects of prehab or rehabilitation on pain and measures of upper extremity mobility and strength after breast cancer surgery	Kelley Wood
P5-07-03: Patient-Reported Outcomes Following Various Breast Reconstruction Techniques: A Retrospective Cohort Study in China	Hongmei Zheng

P5-07-04: Postoperative upper Limb Edema and Dysfunction Generated by axillary nodes Excision in breast cancer patients with high or low proportion of upper limb venous reflux(PLEDGE-Reflux): a multicenter, prospective cohort study	Qianrui Xu
P5-07-05: A Comparison of Wire Guided and Magseed Localisation in Impalpable Breast Lesions	Saira Khawaja
P5-07-06: Long-term follow-up of Immediate lymphaticovenous anastomosis based on Lymphosome Mapping Strategy after axillary lymph node dissection in breast cancer	Richard Chih-Hau Chang
P5-07-07: USING FLUORESCEIN FOR DETECTION OF SENTINEL LYMPH NODES IN COMBINATION WITH TARGETED AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER: PRELIMINARY RESULTS OF EFFICACY AND SAFETY STUDY	Aleksander Soinov
P5-07-08: The ACOSOG Z0011 criteria can be safely applied to Chinese patients: the SAHZU experience	Yue Hu
P5-07-09: Predictive factors for postmastectomy reconstruction after breast cancer in Brazil	Anne Dominique Nascimento Lima
P5-07-10: Immediate Breast Reconstruction with Prepectoral Implant	DANIELLE MAIA
P5-07-11: Comparison of the effectiveness of using visualization methods of the lymphatic tracts of the upper limb in preparation for the application of lymphovenous anastomoses for patients with secondary lymphedema.	Arina Tkachenko
P5-07-12: ONCOPLASTIC SURGERY FOR PAGET'S DISEASE OF THE BREAST	Rafael Pelorca
P5-07-13: Analysis of Single-Port Robot-Assisted Nipple Sparing Mastectomy in Patients with Invasive Breast Cancer: Propensity-Matched Comparison with Conventional Nipple Sparing Mastectomy	Ah Yoon Kim
P5-07-14: Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer	Hui Zhang
P5-07-15: FEASIBILITY AND SAFETY OF ROBOTIC NIPPLE-SPARING MASTECTOMY (RNSM) WITH 1 IMPLANT BASED - IMMEDIATE BREAST RECONSTRUCTION: AN INITIAL EXPERIENCE FROM INDIA'S 1ST ROBOTIC BREAST SURGERY TEAM	PRIYA KAPOOR
P5-07-16: How cardiovascular risk factors and type of chemotherapy influence cardiotoxicity in early HER2 positive breast cancer (HER2+ BC) patients treated with neoadjuvant Trastuzumab and Pertuzumab (T-P) based chemotherapy?	Beatriz Alonso de Castro

P5-07-17: Comparison of Rate of Pathologic Complete Response in HER2-zero versus HER2-low Breast Cancer: a Meta-Analysis	Michelle Min
P5-07-18: HER2DX assay in HER2-positive (HER2+) breast ductal carcinoma in situ (DCIS)	Esther Sanfeliu
P5-07-19: A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer (EBC) in China: NER-Tree study—An interim analysis on safety	Jin Zhang
P5-07-20: A prospective, open-label, single-arm phase II clinical study of inetetamab in combination w/ pyrotinib & albumin-bound paclitaxel for neoadjuvant treatment of patients with HER2+ early & locally advanced breast cancer: updates on clinical trial	Nanlin Li
P5-07-21: Real-World Safety and Effectiveness of Switching among Biosimilars in HER2-Positive Breast Cancer	Andreas Nearchou
P5-07-22: Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01	Snehal Patel
P5-07-23: Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study	Jie Ge
P5-07-24: HER2+ early breast cancer treatment and outcomes by risk of recurrence: a retrospective US electronic health records study	Reshma Mahtani
P5-07-25: "NAVIGATING THE NEXUS: OVERCOMING DOUBLE JEOPARDY OF EARLY HER2-POSITIVE BREAST CANCER PRESENTING AS AN ANTI-Yo POSITIVE PARANEOPLASTIC CEREBELLAR DEGENERATION IN A YOUNG WOMAN"	Vallish Shenoy
P5-07-26: UK 5-Point Scoring System for Clinical Breast Examination Reduces Discordance in a Symptomatic Breast Triple Assessment Clinic	Jaime Castillo
P5-07-27: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Updated results from a phase 1 study	Jiong Wu

P5-07-28: The next-generation CDK4-selective inhibitor atirnociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+/HER2+ metastatic breast cancer	Antonio Giordana
P5-07-29: Trastuzumab deruxtecan With Pembrolizumab in Previously Treated HER2-Expressing Advanced or Metastatic Breast Cancer: Interim Analyses of the Breast Cohorts from the Open-Label, Multicenter, Phase 1b Study DS8201-A-U106	Hope S. Rugo
P5-07-30: Prophylactic irradiation to the contralateral breast for BRCA pathogenic-variant carriers with early-stage breast cancer: 10 years results	Ella Evron
P5-08-01: The Impact of the Neoadjuvant Chemotherapy Compared to Adjuvant Chemotherapy in ALND Candidacy in cN0, cT1,2 early-stage Breast Cancer, A National Cancer Database Analysis	Mahtab Vasigh
P5-08-02: Baseline dietary patterns among patients with early-stage breast cancer in the Healthy Living Program	Bethina Liu
P5-08-03: Significant overall survival (OS) benefit among patients with neoadjuvant chemotherapy use in T1c N0 triple negative and HER2 positive early breast cancer: a large National Cancer Database (NCDB) analysis.	Amalia M. Bonano-Rios
P5-08-04: The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer – A Systematic Review and Meta-Analysis	Danilo Giffoni de Mello Morais Mata
P5-08-05: Impact of Inflammatory Breast Cancer on Survival Outcomes in Metastatic Breast Cancer Patients Treated with Topoisomerase 1 based Antibody-Drug Conjugates (ADCs)	Akshara Singareeka Raghavendra
P5-08-06: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide (TCX) versus anthracycline plus docetaxel & cyclophosphamide regimen (TAC) in women with high-risk, Her2-negative breast cancer: an open-label, randomized controlled trial	Yu Song
P5-08-07: Survival Outcomes of Sequential Topoisomerase I Antibody-Drug Conjugate Therapies in Metastatic Breast Cancer Patients	Akshara Singareeka Raghavendra
P5-08-08: Predicting local recurrence in DCIS treated predominantly without radiation	Christina Kozul
P5-08-09: Validation of the Updated Breast Graded Prognostic Assessment (Breast GPA) for Stereotactic Radiosurgery (SRS) Treated Patients	Ajay Dhakal

P5-08-10: Open	
P5-08-11: Comprehensive characterization of the immune landscape in HER2-low and HER2-0 hormone receptor positive tumors	Carlos Wagner Wanderley
P5-08-12: Association of Baseline Global Inflammation Score with Clinical Outcomes: Secondary Analysis from Alliance A011502	Shipra Gandhi
P5-08-13: Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021	Sagar Sardesai
P5-08-14: Preliminary results of mini-invasive detection of residual disease in breast cancer patients in remission after primary chemotherapy: a further step toward omission of surgery?	Deborah Bonfili
P5-08-15: Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2) negative metastatic breast cancer	Heather Moore
P5-08-16: Best response to antibody-drug conjugates (ADCs), sacituzumab govitecan and trastuzumab deruxtecan, based on organ site of metastatic breast cancer (MBC) involvement	Neelima Vidula
P5-08-17: Effect of vitamin D supplementation on the pathological complete response to neoadjuvant chemotherapy in women with breast cancer: a randomized clinical trial	EDUARDO PESSOA
P5-08-18: Prognostic Value of FDG-PET/CT in Breast Cancer with Unfavorable Special Histology	Mutsumi Fujimoto
P5-08-19: A novel formula to improve the accuracy of predicting survival time after recurrent breast cancer	Reiki Nishimura
P5-08-20: Comparative study of the gut microbiome of newly diagnosed postmenopausal breast cancer patients and healthy controls, and pilot study on the acceptability of soy milk in the patient group	Masahiro Takada
P5-08-21: Analysis of factors influencing the efficacy of NAC and prognosis between HER2-0 and HER2-low HR negative breast cancer	Jingjing Liu
P5-08-22: Effectiveness of Online Education in Improving Clinicians' Knowledge, Competence and Confidence in the Management of Metastatic Breast Cancer	Zhizhi Fiske



P5-08-23: DIHYDROCERAMIDE DESATURASE 1 (DES1) AS A REGULATOR OF CASPASE 14 IS REQUIRED FOR ANCHORAGE-INDEPENDENT SURVIVAL AND METASTASIS OF HER2-POSITIVE AND BASAL BREAST CANCER	Deanna Peperno
P5-08-24: Prognostic Value of the Geriatric Vulnerability Score in Older Patients with Metastatic Breast Cancer	Min Xiao
P5-08-25: Inhibiting Breast Cancer Metastasis by Targeting Chemokine-Glycosaminoglycan Interactions	Mohammed Imad Malki
P5-08-26: Relapse after 10 years following treatment for early breast cancer. 18 years follow-up data from a Belgian single-center.	Patrick Neven
P5-08-27: Reliability of Immunohistochemical Biomarkers in Core Biopsy Versus Surgical Specimens for Breast Cancer: Implications for Treatment Planning	Hagigat Valiyeva
P5-08-28: Randomized phase 2 window of opportunity trial comparing the effect of preoperative atimociclib (PF-07220060) plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2+ breast cancer	Shom Goel
P5-08-29: Assessment of RNA Extraction Protocols from FFPE Breast Cancer Samples with the APIS Breast Cancer Subtyping Kit	Anna Gasior
P5-08-30: The impact of tumor location on survival rates in invasive ductal carcinoma for patients who undergo breast-conserving therapy	Abdulah Jariri
P5-09-01: Some factors associated with re-excision in breast conserving surgery do not increase rates of re-excision after oncoplastic breast conserving surgery: a retrospective study	Kendall Vignaroli
P5-09-02: Acellular Dermal Matrix (Braxon® and STRATTICE™) for immediate implant - based breast reconstruction - Our Initial experience	Asma Munir
P5-09-03: Localization combined with multidetector CT 3-dimensional image reconstruction guided precision breast conserving surgery versus conventional breast conserving surgery: cosmetic analysis of the single center, prospective, cohort study.	Yiqin Xia
P5-09-05: Median Five-Year Follow-Up Outcomes Based on Pathologic Grade in a Multi-Institution Trial Using Intra-Operative Electronic Brachytherapy for Treatment of Early-Stage Breast Cancer	Barbara Schwartzberg

P5-09-06: Acute Cardiovascular Events after Hypofractionated IMRT for Early Breast Cancer: Association with Coronary Calcifications in Radiotherapy Planning-CTs	Ana Aurora Diaz-Gavela
P5-09-07: Patterns of progression after first-line systemic therapy in metastatic breast cancer and the potential of ctDNA to guide metastasis-directed therapy: implications for breast oligometastases management	Jee Suk Chang
P5-09-09: Prospective Evaluation of Shoulder Morbidity in Patients with Lymph Node-Positive Breast Cancer Receiving Regional Nodal Irradiation	Jose Bazan
P5-09-10: Metastasis-directed radiotherapy and systemic treatment continuation for patients with extracranial oligoprogressive metastatic breast cancer (ESTER-RW): a single-center retrospective analysis	Monica Milano
P5-09-11: Cardiac assessment and safety of 5-fraction whole breast irradiation after breast-conserving surgery: an observational prospective cohort study (SAFE-FORWARD)	Icro Meattini, Luca Visani
P5-09-12: Pre-Operative Radiation Boost Planning in a Phase II Clinical Trial Achieves Acceptable Tumor Volume Coverage	Molly Chakraborty
P5-09-13: LumiSystem-guided lumpectomy enables informed customization of radiation therapy in select patients with breast cancer.	Simona Shaitelman
P5-09-15: Impact of Patient Navigation on Radiation Therapy Completion in Black Breast Cancer Patients: Early Phase I Trial Results From the Navigator-Assisted Hypofractionation (NAVAH) Program	Shearwood McClelland III, M.D.
P5-09-16: Real world experience with Carboplatin plus Nab-paclitaxel as neoadjuvant therapy in patients with early triple negative breast cancer.	Manuel Alva Bianchi
P5-09-17: Patterns and Predictors of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer	Lauren Perry
P5-09-18: Real-World Analysis of Patients with Triple-Negative Breast Cancer and Germline BRCA Mutation Undergoing Neoadjuvant Treatment Following the Keynote 522 Protocol	MONIQUE TAVARES
P5-09-19: Survival outcomes of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer and cell-free DNA whole methylome based biomarker analysis: A prospective multi-center cohort study	Xi Chen

P5-09-20: The impact of HER2 expression in early-stage triple negative breast cancer	Hadar Goldvaser
P5-09-20: Hidden Challenge: Atypical Ductal Hyperplasia in Vulvar Ectopic Breast Tissue	Ana Sandoval-Leon
P5-09-23: Programmed death-ligand 1 expression in a Mexican cohort of triple-negative breast cancer	Alejandro Aranda-Gutierrez
P5-09-24: Neoadjuvant (NA) immunotherapy (IO) combined with chemotherapy in triple negative breast cancer (TNBC): A UK real world experience from three centres.	Hossameldin Abdallah
P5-09-25: Immunotherapy in Neoadjuvant Treatment of triple-negative breast cancer: First Insights and Treatment Monitoring with MRI - Single Institution Retrospective Analysis	Bibiana Vertakova Krakovska
P5-09-26: KEYNOTE-522 Regimen Outcomes: Real World Experience from a Single Institution with a Predominantly African American Population	Suvarna Guvvala
P5-09-27: Neoadjuvant versus adjuvant systemic therapy in Stage I triple negative breast cancer - An institutional review	Cydni Rink
P5-09-28: A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer	Guangdong Qiao, Yizi Cong
P5-09-29: Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-Pathological Complete Response HER2-Positive Early Breast Cancer Following Neoadjuvant Therapy: A Multicenter Phase II Study	Chuan Wang
P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study	Laura Huppert
P5-10-03: Impact of gBRCA1/2 Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with Topoisomerase 1 based Antibody-Drug Conjugates (ADCs)	Akshara Singareeka Raghavendra
P5-10-04: Trimodal Therapy is Associated with Higher Overall Survival than Chemotherapy only in Patients with Metastatic Inflammatory Breast Cancer	Eric Schupp
P5-10-05: Differences in drug efficacy between primary and metastatic sites and their prognosis for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017	Kiyo Tanaka

P5-10-06: Retrospective, population-based cohort study on associations between tumor size, receptor status, & regional nodal positivity rates for early-stage breast cancer: implications for decision between upfront surgery vs neoadjuvant systemic therapy	Yerin R. Lee
P5-10-07: Longitudinal survey on supportive care needs and coping strategies in women with recurrent/metastatic breast cancer	Tal Sella
P5-10-08: Real-world clinical outcomes of patients with HER2-BRCAM early breast cancer treated with adjuvant capecitabine	Filipa Lynce
P5-10-09: A comparative analysis of model and age independence of a plasma-based real-time qPCR clinical assay for the non-invasive detection of stage I breast cancer.	Elizabeth Cormier-May
P5-10-10: PELICAN-IPC 2015-016/Oncodistinct-003: a randomized phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer	Alexandre de Nonneville
P5-10-11: Immediate breast reconstruction using smooth round implants: a retrospective analysis	Sardor Abdugafforov
P5-10-12: Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn "Cold" Tumor "Hot" in Metastatic Breast Cancer	Ephraim Parent
P5-10-13: Estimation of biological aging and non-cancer mortality rate in breast cancer survivors due to chemotherapy using a computational model of senescence	Swarnavo Sarkar
P5-10-14: Early Invasive Lobular or Ductal Carcinoma with Differential Clinical Outcomes Across Molecular Subtypes among Young Women Who Received Neoadjuvant Chemotherapy	Jincong Freeman
P5-10-15: Effectiveness and tolerance of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive and HER2-Low Metastatic Breast Cancer (MBC): a large real-life French Cohort Study	Marc-Antoine Benderra
P5-10-16: HER2-Low Breast Cancer: The Impact of Online Education on Oncologists' Knowledge and Confidence in Understanding the Latest Advances and Implications for Practice	Zhizhi Fiske
P5-10-17: Impact of Pathologic Response and Individual Prognosis After Neoadjuvant Treatment (NAT) in Patients (pts) with Early HER2+ and Triple-Negative Breast Cancer (TNBC)	Chiara Corti
P5-10-18: What to measure in Real-World Evidence (RWE) Studies: A Patient Informed Conceptual Disease Model in Early-Stage Breast Cancer	Xiaoqing Xi

P5-10-19: Impact of Online Case-Based Education in Improving Clinicians' Knowledge and Confidence in Managing HER2-Low Metastatic Breast Cancer	Zhizhi Fiske
P5-10-20: Patient awareness of HER2-low in metastatic breast cancer: survey results in a patient-facing app	Heidi Ko
P5-10-21: Efficacy and safety of utidelone plus bevacizumab in the treatment of patients with Her2- metastatic breast cancer study	Shaohua Zhang
P5-10-22: Exploring the landscape of locoregional therapy de-escalation in early breast cancer: a systematic review	Alan David McCrorie
P5-10-23: The Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy (NACT) in Operable Breast Cancer	Richa Jaiswal
P5-10-24: Real-world characteristics and BRCA testing among HER2- early breast cancer patients receiving olaparib or other adjuvant therapy in the US community oncology setting	Matthew Monberg
P5-10-25: Exploring JAM2's Potential in Reducing Breast Cancer Invasiveness through IGF2BP2 Regulation	Yang Peng
P5-10-26: Adverse events in routine real-world clinical practice in patients with HER2-negative early breast cancer according to BRCA status: a retrospective observational study using artificial intelligence in Spain	Meng Ru
P5-10-27: Incidence, risk factors and survival outcomes of Breast Cancer Brain Metastasis: a population-level SEER analysis.	Zunairah Shah
P5-10-28: A retrospective analysis of the association between body composition measures and relative dose intensity of (neo)adjuvant chemotherapy for elderly breast cancer patients	Naomi Dempsey
P5-10-29: Comparative analyses of Van Nuys index and NCCN guidelines in ductal carcinoma in situ in a Brazilian hospital	Marcelo Antonini
P5-10-30: Developing microenvironment-based prognostic biomarkers for early breast cancer	Christina Kozul
P5-11-01: LAD Dose and Cardiotoxicity in Breast Cancer Patients Receiving Radiation	Colleen Conger
P5-11-02: Dosimetric Advantages of Prone 3DCRT APBI: A Comparison with Supine IMRT APBI from the Livi Study	Rufus Banks
P5-11-03: Optimizing Adjuvant Treatment Decisions for Patients With Ductal Carcinoma In Situ Using the Oncotype DCIS Score: An Analysis from the National Cancer Database	Jose Bazan

P5-11-04: SHORT-TERM ECOCARDIOGRAPHIC ALTERATIONS AMONG BREAST CANCER PATIENTS WITH HYPOFRACTIONATED RADIATION THERAPY	Ricardo Mendoza Coronado
P5-11-05: Phase II Trial of Ultrahypofractionated Image-Guided Partial Breast Irradiation Following Lumpectomy with Optional Oncoplastic Reconstruction for Early-Stage Breast Cancer	Rachel Radigan
P5-11-06: Adjuvant radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy; Real World Data	FADWA ABDEL RAHMAN
P5-11-07: A longitudinal analysis of the specific types of anxiety towards radiotherapy in patients with breast cancer before, during, and after radiotherapy	Shi-Jia Wang
P5-11-08: Primary analysis of radiotherapy data from prospective randomized controlled phase III VENUS trial: sentinel lymph node biopsy Versus No axillary surgery in early breast cancer clinically and UltraSonographically node negative	Danielle Araujo
P5-11-09: Evaluating Setup Accuracy via Daily CBCT of SGRT Based Tattooless vs Tattooed (Non-SGRT) Setup for Tangential Whole Breast Radiation	Mona Karim
P5-11-10: Analysis of Daily Setup Errors for Patients Undergoing Left Prone Whole Breast Radiotherapy by BMI	Jared Hunt
P5-11-11: Dual-responsive nanoprobe with oxygen economization capacity for potentiating synergistic-checkpoint-blockade-and-radiotherapy-radiodynamic therapy in breast cancer	Yueyang He
P5-11-12: "Less is More": Multi-institutional Experience with Fast-Forward Dose and Fractionation and the Impact of Dosimetric Parameters on Toxicity in Breast Cancer Patients	Majd Alotaibi
P5-11-13: A Method for Quickly Estimating Lung V20 for Forward-Planned Breast Patients	Michael Karp
P5-11-14: Survival Outcomes of Breast Cancer Patients Underwent Neoadjuvant Radiotherapy vs. Adjuvant Radiotherapy: A Population-based Observational Study	Yue Huang
P5-11-15: Application of in vitro 3D models to study the effect of hypofractionated radiation therapy for breast cancer	Hoang Son Pham
PS-05-16: Outcomes in Elderly Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemo-immunotherapy and Chemotherapy Alone.	Natalia Polidorio
P5-11-17: Clinicopathological characterized by HER2-low-expressing breast cancer in triple-negative breast cancer	Michiko Kato

P5-11-18: Treatment Strategies and Pathologic Responses in Triple-Negative Breast Cancer: A Retrospective Analysis	Luisa Fernanda González-González
P5-11-19: Single arm prospective study evaluating the relationship of MRD via ctDNA and pCR in a diverse early TNBC patients receiving neoadjuvant chemotherapy.	Elizabeth John
P5-11-20: Impact of Immune-Related Adverse Events on Response to Neoadjuvant Chemoimmunotherapy in Triple Negative Breast Cancer	Michelle Sterpi
P5-11-21: Pembrolizumab impact on surgery and radiation therapy in non-metastatic triple negative breast cancer treatment	Alizée Camps--Maléa
P5-11-22: Neoadjuvant chemotherapy and survival outcomes in triple-negative breast cancer: a population-based study (Queensland, Australia).	Larissa Vaz-Goncalves
P5-11-23: Sociodemographic Factors Associated with Adjuvant Chemotherapy Receipt in Stage I Triple Negative Breast Cancer (TNBC)	Candice Thompson
P5-11-24: OUTCOMES IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER WITH DOSE-DENSE AC AS PART OF A PEMBROLIZUMAB-BASED REGIMEN	Danielle Roman
P5-11-25: Impact of Cardiometabolic Comorbidities on Outcomes in Early-Stage Triple Negative Breast Cancer Patients Treated with Neoadjuvant Chemo-immunotherapy (Keynote-522 regimen): A Retrospective Analysis	Asfand Yar Cheema
P5-11-26: Stage-Based Survival Analysis in the TRiple-Negative Breast Cancer PrOspective Registry in Middle East Afrlca (TRIPOLI) Study	Loay Kassem
P5-11-27: Analysis of Nectin-4 and its predictive value of pathological response in early Triple negative (TN) breast cancer	MARIA ISABEL GALLEGOS
P5-11-28: Management of triple-negative breast cancer in renal transplant patients: A case report and multidisciplinary approach	Alexandra Montenegro
P5-11-29: Single center experience of the usage of KEYNOTE-522 regimen in patients with high-risk early stage triple negative breast cancer (TNBC)	Graeme Murray
P5-11-30: Residual Cancer Burden (RCB) with Dose-Dense versus Every 3-Week AC regimen during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer – The Neo-Real Study	Renata Bonadio
P5-12-01: Prognostic implications of tumor size and nodal involvement in invasive lobular carcinoma of breast	Eunhye Kang

P5-12-02: Is BRCA2 a marker for worse prognosis in Breast Cancer?	Fatima Vaz
P5-12-03: Influence of antibiotic use on the efficacy of neoadjuvant chemotherapy in breast cancer	MANUEL ZALABARDO AGUILAR
P5-12-04: BRCA genetic testing and treatment patterns for patients with early-stage HER2-negative breast cancer in the United States (U.S.) community setting, 2016–2022	Kathryn Mishkin
P5-12-05: Current delivery and challenges in breast cancer care in the UK in 2023	Richard Simcock
P5-12-06: Elucidating the role of NEAT1_2 in DCIS malignancy	Aditi Rastogi
P5-12-07: Increase of repeated biopsies in metastatic breast cancer over time: Results from the Austrian AGMT_MBC-Registry	Simon Gampenrieder
P5-12-08: Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer	Ustav Joshi
P5-12-09: Pathologic complete response (pCR) rate in patients with a germline pathogenic variant in ATM and early breast cancer	Haven Garber
P5-12-10: Overall survival in patients with recurrent breast cancer in stage II-III using surveillance imaging detection vs symptomatic disease at a reference hospital in Mexico	Rocio Crystal Grajales Alvarez
P5-12-11: Differences in overall survival between patients with fungating and non-fungating breast cancer with distant metastases at the time of diagnosis	Tamaki Tamanuki
P5-12-12: Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node Negative Microinvasive DCIS	Priyanka Parmar
P5-12-13: Does Ductal Carcinoma in Situ have metastatic potential? A nationwide cancer registry-based study of Ductal Carcinoma in Situ with sentinel lymph node positivity	Merle van Leeuwen
P5-12-14: IMPACT OF HER2-LOW STATUS ON SURVIVORSHIP IN HER2-NEGATIVE EARLY BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT TREATMENT WITHOUT PATHOLOGICAL COMPLETE RESPONSE	Matilde Corianò
P5-12-15: Survival Nomogram Including Lymph Node Ratio for Patients with Invasive Micropapillary Breast Cancer	Yi-Zi Zheng
P5-12-16: Impact of Metastatic Sites Including Brain and Liver in Overall Survival Among Patients With Breast Cancer	Ajay Dhakal
P5-12-17: Breast MRI and FDG-PET/CT for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer	Emel Sezer



P5-12-18: Characteristics, treatments and outcomes of localized synchronous bilateral breast cancers in the CANTO French prospective cohort study	Paul Cottu
P5-12-19: Patient-reported outcomes from CIPHER study evaluating patient attitude about ctDNA testing in early-stage breast cancer	Mridula George
P5-12-20: Clinicopathological Correlates of Immunohistochemistry Subtypes in Ductal Carcinoma In Situ: A Retrospective Analysis	Jehyun Chin
P5-12-21: The utility of antiestrogen therapy in early-stage, pure mucinous carcinomas of the breast	Lyndsay Cooper
P5-12-22: Semi-Quantitative Stratification of Breast Cancer Biomarkers using the APIS Breast Cancer Subtyping Kit	Anna Gasior
P5-12-23: Effectiveness of Online Education in Improving Clinicians' Knowledge and Confidence in Managing Adverse Events Associated with Novel Antibody-Drug Conjugate Therapy for Breast Cancer	Zhizhi Fiske
P5-12-24: Outcomes of Metastatic Breast Cancer Patients Initiated on Inpatient Chemotherapy Due to Visceral Crisis	Jason Mouabbi
P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer	Samantha Fisch
P5-12-26: The Reuse of Cyproheptadine, a First-Generation Antihistamine, as an N-WASP Inhibitor in Breast Cancer Metastasis	Rhiannon Yannan Yu
P5-12-27: HER2 Status and Clinical Outcomes in Breast Cancer: A Retrospective Analysis	Neeharika Makani
P5-12-28: Single Institutional Experience with Metaplastic Breast Cancer Comparing Outcomes based on Timing of Chemotherapy, Chemotherapy Regime and Subtypes of Metaplastic Breast Cancer.	Courtney Pisano
P5-12-29: Treatment outcomes of patients with de novo oligometastatic breast cancer treated with "curative intent" at a single institution	Emily Chen
P5-12-30: Characterizing Metastatic Breast Cancer (MBC) Exceptional Responders	Ahmed Mohamed